AKR1B10, a good prognostic indicator in gastric cancer

Yao, Huang; Xu, Yuqian; Chen, L.-G.; Guan, Tianwang; Ma, Yu-Bin; He, Xu; Xia, Yabin; Tao, Hua; Shao, Qin-shu

doi:10.1016/j.ejso.2013.12.014

Cited by 34 publications

(50 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AKR1B10 also catalyzes the reduction of different types of carbonyl compounds, including products of oxidative stress or drugs (Zhong et al, 2011), as well as participates in the activation of procarcinogens (Quinn, Harvey & Penning, 2008). In comparison with normal tissues, AKR1B10 is considerably overexpressed in several types of cancer such as hepatocellular (Tsuzura et al, 2014), lung, breast, gastric and pancreatic (Yao et al, 2014). Due to the potentiation of these activities, the enzyme is believed to be implicated in the development of these diseases.…”

Section: Discussionmentioning

confidence: 99%

Antioxidant-rich leaf extract ofBarringtonia racemosasignificantly alters thein vitroexpression of genes encoding enzymes that are involved in methylglyoxal degradation III

Kong

Aziz

Razali

et al. 2016

PeerJ

View full text Add to dashboard Cite

BackgroundBarringtonia racemosa is a medicinal plant belonging to the Lecythidaceae family. The water extract of B. racemosa leaf (BLE) has been shown to be rich in polyphenols. Despite the diverse medicinal properties of B. racemosa, information on its major biological effects and the underlying molecular mechanisms are still lacking.MethodsIn this study, the effect of the antioxidant-rich BLE on gene expression in HepG2 cells was investigated using microarray analysis in order to shed more light on the molecular mechanism associated with the medicinal properties of the plant.ResultsMicroarray analysis showed that a total of 138 genes were significantly altered in response to BLE treatment (p < 0.05) with a fold change difference of at least 1.5. SERPINE1 was the most significantly up-regulated gene at 2.8-fold while HAMP was the most significantly down-regulated gene at 6.5-fold. Ingenuity Pathways Analysis (IPA) revealed that “Cancer, cell death and survival, cellular movement” was the top network affected by the BLE with a score of 44. The top five canonical pathways associated with BLE were Methylglyoxal Degradation III followed by VDR/RXR activation, TR/RXR activation, PXR/RXR activation and gluconeogenesis. The expression of genes that encode for enzymes involved in methylglyoxal degradation (ADH4, AKR1B10 and AKR1C2) and glycolytic process (ENO3, ALDOC and SLC2A1) was significantly regulated. Owing to the Warburg effect, aerobic glycolysis in cancer cells may increase the level of methylglyoxal, a cytotoxic compound.ConclusionsBLE has the potential to be developed into a novel chemopreventive agent provided that the cytotoxic effects related to methylglyoxal accumulation are minimized in normal cells that rely on aerobic glycolysis for energy supply.

show abstract

Section: Discussionmentioning

confidence: 99%

Antioxidant-rich leaf extract ofBarringtonia racemosasignificantly alters thein vitroexpression of genes encoding enzymes that are involved in methylglyoxal degradation III

Kong

Aziz

Razali

et al. 2016

PeerJ

View full text Add to dashboard Cite

show abstract

“…78 inhibited tumor proliferation [12]. The expression of AKR1B10 was 79 significantly lower in gastric cancer than in paired, normal mucosa 80 [13]. In either case, the low expression of AKR1B10 was correlated 81 with decreased survival and a poor prognosis.…”

mentioning

confidence: 93%

Down-regulation of aldo–keto reductase AKR1B10 gene expression by a phorbol ester via the ERK/c-Jun signaling pathway

Nishinaka

Miura

Sakou

et al. 2015

Chemico-Biological Interactions

View full text Add to dashboard Cite

“…AKR1B10 is overexpressed in many non-digestive tract solid cancers such as hepatocellular carcinoma [2], various types of lung cancer including lung squamous cell carcinomas [12] and smoking related lung adenocarcinomas [13], cholangiocarcinomas [12], pancreatic carcinomas [14], and breast carcinomas [15]. On the contrary, the expression of AKR1B10 is downregulated in gastrointestinal cancer [16,17]. AKR1B10 overexpression has been considered as a valuable biomarker and prognostic indicator for some cancers [15,17,18], and low expression of AKR1B10 has been used as a biomarker for the diagnosis of bowel diseases (US8551720) [19].…”

Section: Introductionmentioning

confidence: 98%

“…Curcumin and curcumin-like derivatives were tested to target AKR1B10 with high affinities [97]. Curcuminoids, magnolol (15), honokiol (16) and resveratrol (17) are active substances with higher efficiency for AKR1B10 than for AKR1B1 [24]. Among them, bisdemethoxycurcumin (BDMC, 18) (CN104591987) [98] is the most prominent one, showing an AKR1B10/AKR1B1 selectivity ratio of 85 and a low IC 50 value.…”

Section: Natural-based Derivativesmentioning

confidence: 99%

“…On the contrary, the expression of AKR1B10 is downregulated in gastrointestinal cancer [16,17]. AKR1B10 overexpression has been considered as a valuable biomarker and prognostic indicator for some cancers [15,17,18], and low expression of AKR1B10 has been used as a biomarker for the diagnosis of bowel diseases (US8551720) [19]. AKR1B10 is a protein secreted through a lysosome-mediated pathway and may serve as a potential serum marker for malignant diseases [20].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment

Li¹,

He²,

Luo³

et al. 2016

PRA

View full text Add to dashboard Cite

Cytosolic NADPH-dependent reductase AKR1B10 is a member of the aldo-keto reductase (AKR) superfamily. This enzyme is normally expressed in the gastrointestinal tract. However, it is overexpressed in many solid tumors, such as hepatocarcinoma, lung cancer and breast cancer. AKR1B10 may play a role in the formation and development of carcinomas through multiple mechanisms including detoxification of cytotoxic carbonyls, modulation of retinoic acid level, and regulation of cellular fatty acid synthesis and lipid metabolism. Studies have suggested that AKR1B10 may be a useful biomarker for cancer diagnosis and a potential target for cancer treatment. Over the last decade, a number of AKR1B10 inhibitors including aldose reductase inhibitors (ARIs), endogenous substances, natural-based derivatives and synthetic compounds have been developed, which could be novel anticancer drugs. This review provides an overview on related articles and patents about AKR1B10 inhibitors, with a focus on their inhibition selectivity and mechanism of function.

show abstract

AKR1B10, a good prognostic indicator in gastric cancer

Cited by 34 publications

References 39 publications

Antioxidant-rich leaf extract ofBarringtonia racemosasignificantly alters thein vitroexpression of genes encoding enzymes that are involved in methylglyoxal degradation III

Antioxidant-rich leaf extract ofBarringtonia racemosasignificantly alters thein vitroexpression of genes encoding enzymes that are involved in methylglyoxal degradation III

Down-regulation of aldo–keto reductase AKR1B10 gene expression by a phorbol ester via the ERK/c-Jun signaling pathway

Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment

Contact Info

Product

Resources

About